A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 101–200 of 3,965
Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease
Kai, F., Laklai, H., & Weaver, V. M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.03.007 · Cited by 243
“More recently, pirfenidone, which also reduces TGF-b as well as TNF/ activity, was developed as a US Food and Drug Administration (FDA)-approved antifibrotic treatment for idiopathic pulmonary fibrosis with fewer adverse effects [84,85], although its clinical efficacy and applicability for other fibrotic diseases have…”
BackgroundSalisbury, M. L., Myers, J. L., Belloli, E. A., Kazerooni, E. A., Martinez, F. J., & Flaherty, K. R. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1675pp · Cited by 243
Evans, C. M., Fingerlin, T. E., Schwarz, M. I., Lynch, D., Kurche, J., Warg, L., Yang, I. V., & Schwartz, D. A. (2016) · Physiological Reviews · doi:10.1152/physrev.00004.2016 · Cited by 238
Anti-TNFα therapy in inflammatory lung diseases
Malaviya, R., Laskin, J. D., & Laskin, D. L. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.008 · Cited by 235
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Kolb, M., Richeldi, L., Behr, J., Maher, T. M., Tang, W., Stowasser, S., Hallmann, C., & du Bois, R. M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208710 · Cited by 235
Visca, D., Mori, L., Tsipouri, V., Fleming, S., Firouzi, A., Bonini, M., Pavitt, M. J., Alfieri, V., Canu, S., Bonifazi, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30289-3 · Cited by 235
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Ahluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01592-2016 · Cited by 233
Self-citationMaher, T. M., van der Aar, E. M., Van de Steen, O., Allamassey, L., Desrivot, J., Dupont, S., Fagard, L., Ford, P., Fieuw, A., & Wuyts, W. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30181-4 · Cited by 231
Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice
Hancock, L. A., Hennessy, C. E., Solomon, G. M., Dobrinskikh, E., Estrella, A., Hara, N., Hill, D. B., Kissner, W. J., Markovetz, M. R., Grove Villalon, D. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07768-9 · Cited by 233
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
Strongman, H., Kausar, I., & Maher, T. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0693-1 · Cited by 233
Metformin attenuates lung fibrosis development via NOX4 suppression
Sato, N., Takasaka, N., Yoshida, M., Tsubouchi, K., Minagawa, S., Araya, J., Saito, N., Fujita, Y., Kurita, Y., Kobayashi, K., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0420-x · Cited by 228
The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis
Murtha, L. A., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Knight, D. A., & Boyle, A. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00777 · Cited by 229
Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312346 · Cited by 227
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vasakova, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2018) · JAMA · doi:10.1001/jama.2018.6129 · Cited by 227
Cottin, V., Selman, M., Inoue, Y., Wong, A. W., Corte, T. J., Flaherty, K. R., Han, M. K., Jacob, J., Johannson, K. A., Kitaichi, M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202206-1041st · Cited by 226
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Petnak, T., Lertjitbanjong, P., Thongprayoon, C., & Moua, T. (2021) · Chest · doi:10.1016/j.chest.2021.06.049 · Cited by 220
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
Hirani, N., MacKinnon, A. C., Nicol, L., Ford, P., Schambye, H., Pedersen, A., Nilsson, U. J., Leffler, H., Sethi, T., Tantawi, S., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02559-2020 · Cited by 220
COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts
John, A. E., Joseph, C., Jenkins, G., & Tatler, A. L. (2021) · Immunological Reviews · doi:10.1111/imr.12977 · Cited by 219
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis
Kreuter, M., Wuyts, W., Renzoni, E., Koschel, D., Maher, T. M., Kolb, M., Weycker, D., Spagnolo, P., Kirchgaessler, K.-U., Herth, F. J. F., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00067-9 · Cited by 218
Detection of Rheumatoid Arthritis–Interstitial Lung Disease Is Enhanced by Serum Biomarkers
Doyle, T. J., Patel, A. S., Hatabu, H., Nishino, M., Wu, G., Osorio, J. C., Golzarri, M. F., Traslosheros, A., Chu, S. G., Frits, M. L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-1950oc · Cited by 215
Solomon, J. J., Danoff, S. K., Woodhead, F. A., Hurwitz, S., Maurer, R., Glaspole, I., Dellaripa, P. F., Gooptu, B., Vassallo, R., Cox, P. G., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00260-0 · Cited by 216
Self-citationSafety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00198013 · Cited by 215
Mesothelial cells in tissue repair and fibrosis
Mutsaers, S. E., Birnie, K., Lansley, S., Herrick, S. E., Lim, C.-B., & Prêle, C. M. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00113 · Cited by 210
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R., Ebner, T., Stopfer, P., & Dallinger, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00766-0 · Cited by 212
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
Lewis, G. A., Dodd, S., Clayton, D., Bedson, E., Eccleson, H., Schelbert, E. B., Naish, J. H., Jimenez, B. D., Williams, S. G., Cunnington, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01452-0 · Cited by 209
Signaling Pathways Involved in Diabetic Renal Fibrosis
Zhang, Y., Jin, D., Kang, X., Zhou, R., Sun, Y., Lian, F., & Tong, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696542 · Cited by 210
“In terms of adverse effects of Pirfenidone, gastrointestinal disorder (King et al., 2014), skin-related disease, and fatigue (Maher et al.”
BackgroundDefining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing
Peyser, R., MacDonnell, S., Gao, Y., Cheng, L., Kim, Y., Kaplan, T., Ruan, Q., Wei, Y., Ni, M., Adler, C., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0313oc · Cited by 210
Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0621-y · Cited by 210
Self-citationDissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey
Cosgrove, G. P., Bianchi, P., Danese, S., & Lederer, D. J. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0560-x · Cited by 208
Self-citationExploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Finnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A., & Kamil, H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01783-1 · Cited by 209
Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
Ryerson, C. J., Cottin, V., Brown, K. K., & Collard, H. R. (2015) · European Respiratory Journal · doi:10.1183/13993003.00419-2015 · Cited by 205
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Ley, B., Swigris, J., Day, B.-M., Stauffer, J. L., Raimundo, K., Chou, W., & Collard, H. R. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0091oc · Cited by 206
Self-citationTransbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases
Maldonado, F., Danoff, S. K., Wells, A. U., Colby, T. V., Ryu, J. H., Liberman, M., Wahidi, M. M., Frazer, L., Hetzel, J., Rickman, O. B., et al. (2020) · Chest · doi:10.1016/j.chest.2019.10.048 · Cited by 200
Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis
Jacob, J., Bartholmai, B. J., Rajagopalan, S., van Moorsel, C. H. M., van Es, H. W., van Beek, F. T., Struik, M. H. L., Kokosi, M., Egashira, R., Brun, A. L., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2174oc · Cited by 198
Computed Tomography: Revolutionizing the Practice of Medicine for 40 Years
Rubin, G. D. (2014) · Radiology · doi:10.1148/radiol.14141356 · Cited by 197
Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T. R., Brauer, M. J., Hunkapiller, J., Reeder, J., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30135-8 · Cited by 196
Self-citationTime for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30007-9 · Cited by 196
Self-citationBehr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Herzog, E. L., Mathur, A., Tager, A. M., Feghali‐Bostwick, C., Schneider, F., & Varga, J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38702 · Cited by 193
Cardiac fibrosis: potential therapeutic targets
Park, S., Nguyen, N. B., Pezhouman, A., & Ardehali, R. (2019) · Translational Research · doi:10.1016/j.trsl.2019.03.001 · Cited by 194
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
“…Treatment of idiopathic pulmonary fibrosis (IPF) has been transformed by the use of the small molecule inhibitors pirfenidone and nintedanib (King et al, 2014; Flaherty et al, 2019), and tranilast has been used in the treatment of asthma and keloid scars for over 30 years in Japan…”
BackgroundBTS Clinical Statement on pulmonary sarcoidosis
Thillai, M., Atkins, C. P., Crawshaw, A., Hart, S. P., Ho, L.-P., Kouranos, V., Patterson, K. C., Screaton, N. J., Whight, J., & Wells, A. U. (2021) · Thorax · doi:10.1136/thoraxjnl-2019-214348 · Cited by 194
The genetic basis of idiopathic pulmonary fibrosis
Kropski, J. A., Blackwell, T. S., & Loyd, J. E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00163814 · Cited by 193
Paterniti, M. O., Bi, Y., Rekić, D., Wang, Y., Karimi-Shah, B. A., & Chowdhury, B. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-458oc · Cited by 194
Idiopathic Pulmonary Fibrosis – Diagnosis and Treatment
Bendstrup, E. (2014) · General Medicine: Open Access · doi:10.4172/2327-5146.1000161 · Cited by 192
“During the last 10-15 years, an increasing number of randomised, placebo-controlled trials in IPF have been published, culminating in 2014 with the publication of three studies of which two were positive and showed a reduced disease progression of IPF [12,13].”
BackgroundNatural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191
Mitochondrial quality control in pulmonary fibrosis
Larson-Casey, J. L., He, C., & Carter, A. B. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101426 · Cited by 189
Hansell, D. M., Goldin, J. G., King, T. E., Lynch, D. A., Richeldi, L., & Wells, A. U. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00096-x · Cited by 189
Self-citationTreatment of primary Sjögren syndrome
Saraux, A., Pers, J.-O., & Devauchelle-Pensec, V. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.100 · Cited by 188
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D., Atwood, M., Kirchgaessler, K.-U., & Maher, T. M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0669oc · Cited by 187
Drug Treatment of Idiopathic Pulmonary Fibrosis
Canestaro, W. J., Forrester, S. H., Raghu, G., Ho, L., & Devine, B. E. (2016) · Chest · doi:10.1016/j.chest.2015.11.013 · Cited by 186
Romagnoli, M., Colby, T. V., Berthet, J.-P., Gamez, A. S., Mallet, J.-P., Serre, I., Cancellieri, A., Cavazza, A., Solovei, L., Dell’Amore, A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1947oc · Cited by 187
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
Schmidkonz, C., Rauber, S., Atzinger, A., Agarwal, R., Götz, T. I., Soare, A., Cordes, M., Prante, O., Bergmann, C., Kleyer, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217408 · Cited by 187
Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
King, C. S., & Nathan, S. D. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30222-3 · Cited by 186
Self-citationProgression of fibrosing interstitial lung disease
Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-1296-3 · Cited by 185
Kadota, T., Fujita, Y., Araya, J., Watanabe, N., Fujimoto, S., Kawamoto, H., Minagawa, S., Hara, H., Ohtsuka, T., Yamamoto, Y., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12124 · Cited by 187
“…treatment modalities, such as pir-fenidone (PFD) and nintedanib, significantly reduce the decline of forced vital capacity, these drugs neither promote recovery nor prevent the progression of functional decline and the structural distortion seen in IPF (King et al., 2014; Richeldi et al., 2014).”
Raghu, G., & Selman, M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2044ed · Cited by 185
Mesoporous silica nanoparticles for pulmonary drug delivery
García-Fernández, A., Sancenón, F., & Martínez-Máñez, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113953 · Cited by 183
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Lawrence, J., & Nho, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183
Acute exacerbations of progressive-fibrosing interstitial lung diseases
Kolb, M., Bondue, B., Pesci, A., Miyazaki, Y., Song, J. W., Bhatt, N. Y., Huggins, J. T., Oldham, J. M., Padilla, M. L., Roman, J., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0071-2018 · Cited by 182
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Glasscock, K. F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207011 · Cited by 180
Self-citationDaily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
Grimminger, F., Günther, A., & Vancheri, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00149614 · Cited by 178
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review
Kinoshita, T., & Goto, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061461 · Cited by 176
Therapeutic targets for treating fibrotic kidney diseases
Lee, S.-Y., Kim, S. I., & Choi, M. E. (2015) · Translational Research · doi:10.1016/j.trsl.2014.07.010 · Cited by 176
Désogère, P., Tapias, L. F., Hariri, L. P., Rotile, N. J., Rietz, T. A., Probst, C. K., Blasi, F., Day, H., Mino-Kenudson, M., Weinreb, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4696 · Cited by 175
“Recently, the Food and Drug Administration approved two different therapeutic agents for the treatment of IPF in the United States, pirfenidone and nintedanib, largely based on results from the CAPACITY (43), ASCEND (44) and INPULSIS trials (45).”
BackgroundWinterbottom, C. J., Shah, R. J., Patterson, K. C., Kreider, M. E., Panettieri, R. A., Rivera-Lebron, B., Miller, W. T., Litzky, L. A., Penning, T. M., Heinlen, K., et al. (2018) · Chest · doi:10.1016/j.chest.2017.07.034 · Cited by 173
“In cases of diagnostic uncertainty, a comprehensive review of clinical history and radiological and surgical pathologic examination were presented to a multidisciplinary committee, including at least two ILD clinicians, a dedicated chest radiologist, and a pathologist, for adjudication based on 2011 ATS IPF criteria.”
InfluentialSelvarajah, B., Azuelos, I., Platé, M., Guillotin, D., Forty, E. J., Contento, G., Woodcock, H. V., Redding, M., Taylor, A., Brunori, G., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav3048 · Cited by 172
“Although the approval of pirfenidone and the small molecule tyrosine kinase inhibitor, nintedanib, for the treatment of IPF represented a watershed moment for the development of anti-fibrotic therapeutics, these agents slow but do not halt disease progression (4, 5).”
BackgroundCardiac Fibrosis and Fibroblasts
Kurose, H. (2021) · Cells · doi:10.3390/cells10071716 · Cited by 171
Transcriptional regulatory model of fibrosis progression in the human lung
McDonough, J. E., Ahangari, F., Li, Q., Jain, S., Verleden, S. E., Herazo-Maya, J., Vukmirovic, M., DeIuliis, G., Tzouvelekis, A., Tanabe, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131597 · Cited by 174
“by convincing evidence that immunosuppressive therapies have a detrimental effect on the patient and that recently developed antifibrotic drugs are effective in slowing the progression of the disease (6, 7).”
BackgroundPulmonary Rehabilitation in Interstitial Lung Disease
Koltharkar, M. (2021) · International Journal of Cardiovascular Research · Cited by 173
Acute Exacerbation in Interstitial Lung Disease
Leuschner, G., & Behr, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00176 · Cited by 171
Quantitative CT Analysis of Diffuse Lung Disease
Chen, A., Karwoski, R. A., Gierada, D. S., Bartholmai, B. J., & Koo, C. W. (2020) · RadioGraphics · doi:10.1148/rg.2020190099 · Cited by 168
Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production
Nigdelioglu, R., Hamanaka, R. B., Meliton, A. Y., O'Leary, E., Witt, L. J., Cho, T., Sun, K., Bonham, C., Wu, D., Woods, P. S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.756247 · Cited by 169
Inui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
Rogliani, P., Calzetta, L., Cavalli, F., Matera, M. G., & Cazzola, M. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.07.009 · Cited by 168
Hughes, G., Toellner, H., Morris, H., Leonard, C., & Chaudhuri, N. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090078 · Cited by 166
Albera, C., Costabel, U., Fagan, E. A., Glassberg, M. K., Gorina, E., Lancaster, L., Lederer, D. J., Nathan, S. D., Spirig, D., & Swigris, J. J. (2016) · European Respiratory Journal · doi:10.1183/13993003.01966-2015 · Cited by 166
Self-citationLysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis
Tjin, G., White, E. S., Faiz, A., Sicard, D., Tschumperlin, D. J., Mahar, A., Kable, E. P. W., & Burgess, J. K. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030114 · Cited by 163
“…of two recently approved drugs for slowing the progress of IPF [nintedanib (Mazzei et al., 2015; Richeldi et al., 2014a,b) and pirfenidone (King et al., 2014; Valeyre et al., 2014)], their associated incidence of side effects and modest clinical benefit warrants further investigation into…”
Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis
Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Burgess, J. K., Mutsaers, S. E., Prele, C. M., Schuliga, M., Grainge, C. L., & Knight, D. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2018 · Cited by 163
Vannan, A., Lyu, R., Williams, A. L., Negretti, N. M., Mee, E. D., Hirsh, J., Hirsh, S., Hadad, N., Nichols, D. S., Calvi, C. L., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02080-x · Cited by 161
Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis
Wang, J. M., Robertson, S. H., Wang, Z., He, M., Virgincar, R. S., Schrank, G. M., Smigla, R. M., O’Riordan, T. G., Sundy, J., Ebner, L., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210070 · Cited by 162
Chung, J. H., Cox, C. W., Montner, S. M., Adegunsoye, A., Oldham, J. M., Husain, A. N., Vij, R., Noth, I., Lynch, D. A., & Strek, M. E. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.17.18384 · Cited by 163
Pulmonary fibrosis secondary to COVID-19: a narrative review
Tanni, S. E., Fabro, A. T., de Albuquerque, A., Ferreira, E. V. M., Verrastro, C. G. Y., Sawamura, M. V. Y., Ribeiro, S. M., & Baldi, B. G. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1916472 · Cited by 161
Sisson, T. H., Ajayi, I. O., Subbotina, N., Dodi, A. E., Rodansky, E. S., Chibucos, L. N., Kim, K. K., Keshamouni, V. G., White, E. S., Zhou, Y., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.12.005 · Cited by 158
Li, Y., Li, H., Liu, S., Pan, P., Su, X., Tan, H., Wu, D., Zhang, L., Song, C., Dai, M., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.05.003 · Cited by 158
“Pirfenidone, with an acceptable side-effect profile (King et al., 2014), is an oral antifibrosis drug that is successfully applied to the treatment of idiopathic”
Interstitial Lung Abnormalities: State of the Art
Hata, A., Schiebler, M. L., Lynch, D. A., & Hatabu, H. (2021) · Radiology · doi:10.1148/radiol.2021204367 · Cited by 160
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Nikitin, A., Sotnikova, A., Kotova, S., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0037 · Cited by 158
“Moreover, our patients in general belonged to a more severely impaired functional category than those who participated in studies of the antifibrotic drugs nintedanib and pirfenidone, which were approved for IPF treatment.(10,11) One unusual case, a 33-year-old man, a surgeon, with HRCT findings of definite UIP, witho…”
BackgroundInhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung
Popowski, K. D., López de Juan Abad, B., George, A., Silkstone, D., Belcher, E., Chung, J., Ghodsi, A., Lutz, H., Davenport, J., Flanagan, M., et al. (2022) · Extracellular Vesicle · doi:10.1016/j.vesic.2022.100002 · Cited by 158
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, T. M., Sangaralingham, L. R., Yao, X., Sanghavi, D., Shah, N. D., & Limper, A. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0456oc · Cited by 156
Du, J., Paz, K., Flynn, R., Vulic, A., Robinson, T. M., Lineburg, K. E., Alexander, K. A., Meng, J., Roy, S., Panoskaltsis-Mortari, A., et al. (2017) · Blood · doi:10.1182/blood-2017-01-758854 · Cited by 155
Williamson, J. D., Sadofsky, L. R., & Hart, S. P. (2014) · Experimental Lung Research · doi:10.3109/01902148.2014.979516 · Cited by 176
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity
Cui, L., Chen, S.-Y., Lerbs, T., Lee, J.-W., Domizi, P., Gordon, S., Kim, Y.-H., Nolan, G., Betancur, P., & Wernig, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16466-4 · Cited by 153
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.